Exploring 25I-NBOMe. To explore a different substance…

Names:
25I-NB2OMe
25I-NBOMe
INBMeO
NBOMe-2CI
Cimbi-5-2
Cimbi-5
N-(2-Methoxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine
4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
IUPAC names:
2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethan-1-amine
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine
ID: 5380 · Formula: C18H22INO3 · Molecular weight: 427.277
InChI: InChI=1S/C18H22INO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3

Anon. New drugs in Europe, 2012, European Monitoring Centre for Drugs and Drug Addiction, 1 May 2013. 773 kB. #32

Nichols, DE; Sassano, MF; Halberstadt, AL; Klein, LM; Brandt, SD; Elliott, SP; Fiedler, WJ. N-Benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues. ACS Chem. Neurosci., 15 Jul 2015, 6 (7), 1165-1175. 406 kB. https://doi.org/10.1021/cn500292d

Brandt, SD; Elliott, SP; Kavanagh, PV; Dempster, NM; Meyer, MR; Maurer, HH; Nichols, DE. Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines. Rapid Commun. Mass Spectrom., 2 Mar 2015, 29 (7), 573–584. 2.2 MB. https://doi.org/10.1002/rcm.7134

Chapman, SJ; Avanes, AA. PeakAL: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra. BLOTTER, 1 Aug 2015, 1 (1). 2.6 MB. https://doi.org/10.16889/isomerdesign-1 Open access DOI

Chapman, SJ; Avanes, AA. PeakAL: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra. Supplementary Data. BLOTTER, 1 Aug 2015, 1 (1). 11.9 MB. https://doi.org/10.16889/isomerdesign-1-supp Open access DOI

Hays, PA; Casale, JF. Characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) derivatives and differentiation from their 3-and 4-methoxybenzyl analogues - Part II. Microgram J., 1 Jan 2014, 11 (1–4), 3–22. 8.1 MB.

Prabhakaran, J; Underwood, MD; Kumar, JSD; Simpson, NR; Kassir, SA; Bakalian, MJ; Mann, JJ; Arango, V. Synthesis and in vitro evaluation of [18F]FECIMBI-36: A potential agonist PET ligand for 5-HT2A/2C receptors. Bioorg. Med. Chem. Lett., 15 Sep 2015, 25 (18), 3933–3936. 603 kB. https://doi.org/10.1016/j.bmcl.2015.07.034

Kaizaki-Mitsumoto, A; Noguchi, N; Yamaguchi, S; Odanaka, Y; Matsubayashi, S; Kumamoto, H; Fukuhara, K; Funada, M; Wada, K; Numazawa, S. Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market. Forensic Toxicol., 1 Jan 2016, 34 (1), 108-114. 854 kB. https://doi.org/10.1007/s11419-015-0293-6

Nielsen, LM; Holm, NB; Leth-Petersen, S; Kristensen, JL; Olsen, L; Linnet, K. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH. Drug Test. Analysis, 1 Jan 2016, 9 (5), 671-679. 553 kB. https://doi.org/10.1002/dta.2031

Halberstadt, AL. Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens. In Current Topics in Behavioral Neurosciences; , 2016; pp 1–29. 826 kB. https://doi.org/10.1007/7854_2016_64

Halberstadt, AL; Geyer, MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology, 1 Feb 2014, 77, 200–207. 1.4 MB. https://doi.org/10.1016/j.neuropharm.2013.08.025

Wohlfarth, A; Roman, M; Andersson, M; Kugelberg, FC; Diao, X; Carlier, J; Eriksson, C; Wu, X; Konradsson, P; Josefsson, M; Huestis, MA; Kronstrand, R. 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry. Drug Test. Analysis, 1 Jan 2016, 9 (5), 680-698. 837 kB. https://doi.org/10.1002/dta.2044

Hyperlab. Hyperlab new compounds. 29 Sep 2014. 232 kB. Note: Contains links to hyperlab.info that require elevated access/karma to follow.

Edmunds, R; Donovan, R; Reynolds, D. The analysis of illicit 25X-NBOMe seizures in Western Australia. Drug Test. Analysis, 20 Aug 2017, n/a-n/a. 481 kB. https://doi.org/10.1002/dta.2260

Martins, D; Barratt, MJ; Pires, CV; Carvalho, H; Ventura, M; Fornís, I; Valente, H. The detection and prevention of unintentional consumption of DOx and 25x-NBOMe at Portugal’s Boom Festival. Hum. Psychopharmacol. Clin. Exp., 1 May 2017, 32 (3), e2608. 400 kB. https://doi.org/10.1002/hup.2608

Leth-Petersen, S; Bundgaard, C; Hansen, M; Carnerup, MA; Kehler, J; Kristensen, JL. Correlating the metabolic stability of psychedelic 5-HT2A agonists with anecdotal reports of human oral bioavailability. Neurochem. Res., 12 Feb 2014, 39 (10), 2018-2023. 625 kB. https://doi.org/10.1007/s11064-014-1253-y

Anon. Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), European Monitoring Centre for Drugs and Drug Addiction, Apr 2014. 500 kB.

Heim, R; Pertz, H; Elz, MZS. Stereoselective synthesis, absolute configuration and 5-HT2A-receptor agonism of chiral 2-methoxybenzylamines. Arch. Pharm. Pharm. Med. Chem., Oct 2002, 335 (Suppl. 1), 82. 573 kB. Poster abstract

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8.4 MB.

Ettrup, A; Hansen, M; Santini, MA; Paine, J; Gillings, N; Palner, M; Lehel, S; Herth, MM; Madsen, J; Kristensen, JL; Begtrup, M; Knudsen, GM. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur. J. Nucl. Med. Mol. Imaging, 1 Apr 2011, 38 (4), 681–693. 752 kB. https://doi.org/10.1007/s00259-010-1686-8

Heim, R. Synthesis and pharmacology of potent 5-HT2A receptor agonists with N-2-methoxybenzyl partial structure. SC. D. Thesis, Freie Universität, Berlin, 1 Jan 2004. 3.9 MB. In German.

Blaazer, AR; Smid, P; Kruse, CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT2A receptors. ChemMedChem, 15 Sep 2008, 3 (9), 1299–1309. 461 kB. https://doi.org/10.1002/cmdc.200800133

Anon. JW, Personal communication of unpublished research. 1 Dec 2011.

Silva, ME. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Ph. D. Thesis, Universität Regensburg, Regensburg, Germany, 26 Aug 2008. 5.9 MB.

Braden, MR; Parrish, JC; Naylor, JC; Nichols, DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol. Pharmacol., 1 Jan 2006, 70 (6), 1956–1964. 361 kB. https://doi.org/10.1124/mol.106.028720

Silva, ME; Heim, R; Strasser, A; Elz, S; Dove, S. Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. J. Comput. Aided Mol. Des., 1 Jan 2011, 25 (1), 51–66. 834 kB. https://doi.org/10.1007/s10822-010-9400-2

Hansen, M. Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain. Ph. D. Thesis, University of Copenhagen, 16 Dec 2012. 7.9 MB.

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5.5 MB.

Casale, JF; Hays, PA. Characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) derivatives and differentiation from their 3- and 4-methoxybenzyl analogues—Part I. Microgram J., 1 Jan 2012, 9 (2), 84–109. 4.6 MB.

Ettrup, A; Palner, M; Gillings, N; Santini, MA; Hansen, M; Kornum, BR; Rasmussen, LK; Nagren, K; Madsen, J; Begtrup, M; Knudsen, GM. Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J. Nucl. Med., 1 Nov 2010, 51 (11), 1763–1770. 548 kB. https://doi.org/10.2967/jnumed.109.074021

Heim, R; Elz, S. Novel extremely potent partial 5-HT2A-receptor agonists: Successful application of a new structure-activity concept. Arch. Pharm. Pharm. Med. Chem., Mar 2000, 333 (Suppl. 1), 18. 566 kB. Poster abstract

Nichols, DE; Frescas, SP; Chemel, BR; Rehder, KS; Zhong, D; Lewin, AH. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): A high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg. Med. Chem., 1 Jan 2008, 16 (10), 6116–6123. 251 kB. https://doi.org/10.1016/j.bmc.2008.04.050

2C-I
25I-NBOH
25I-N2Nap · 25I-NNap
INBMDO · 25I-NBMD
25I-NMeFur
25I-NMeThiop
25I-NMePyr
25I-NBCN
25I-NBAm
25I-NMeInd
25I-N1Nap
25I-NBMeOH
25I-NDHF
25I-N2Nap3OH
25I-N1Nap2OH
25I-NBOH45MD
25I-N2Nap1OH
25I-NB34MD
25I-NBpTFM
25I-NBTFM
25I-NBF
25I-NB4F · 25I-NBpF
25I-NB
25I-N4MT3M
25I-N3MT2M
25I-NEPOMe
25I-NB3OMe
25I-NB4OMe
25I-NB4B
25I-NB3B
25I-NBBr · 25I-NB2B
DOI-NBOMe
DMPEA-NBOMe · 25H-NBOMe
25B-NB2OMe · 25B-NBOMe
25D-NBOMe
25C-NB2OMe · 25C-NBOMe
25E-NBOMe
25T4-NBOMe
25EF-NBOMe
25TFM-NBOMe
25IP-NBOMe
25CN-NBOMe
25F-NBOMe
25N-NBOMe
245-NBOMe
25P-NBOMe
25T-NBOMe
25T2-NBOMe
25T7-NBOMe
IBOX
738
25I-NBMeOH
DOI-NBOH
25I-NB3OMe
25I-NB4OMe
2C-I
25I-NBOH
25I-N2Nap · 25I-NNap
INBMDO · 25I-NBMD
25I-NMeFur
25I-NMeThiop
25I-NMePyr
25I-NBCN
25I-NBAm
25I-NMeInd
25I-N1Nap
25I-NBMeOH
25I-NDHF
25I-N2Nap3OH
25I-N1Nap2OH
25I-NBOH45MD
25I-N2Nap1OH
25I-NB34MD
25I-NBpTFM
25I-NBTFM
25I-NBF
25I-NB4F · 25I-NBpF
25I-NB
25I-N4MT3M
25I-N3MT2M
25I-NEPOMe
25I-NB3OMe
25I-NB4OMe
25I-NB4B
25I-NB3B
25I-NBBr · 25I-NB2B
DOI-NBOMe
DMPEA-NBOMe · 25H-NBOMe
25B-NB2OMe · 25B-NBOMe
25D-NBOMe
25C-NB2OMe · 25C-NBOMe
25E-NBOMe
25T4-NBOMe
25EF-NBOMe
25TFM-NBOMe
25IP-NBOMe
25CN-NBOMe
25F-NBOMe
25N-NBOMe
245-NBOMe
25P-NBOMe
25T-NBOMe
25T2-NBOMe
25T7-NBOMe
IBOX
738
25I-NBMeOH
DOI-NBOH
25I-NB3OMe
25I-NB4OMe
22 February 2018 · Creative Commons BY-NC-SA ·